"It is integrated into everything that we do," says Merck's chief information and digital officer Dave Williams.

We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...

Zacks Research lowered their Q3 2024 earnings estimates for Merck & Co., Inc. in a report issued on Monday, October 21st.

Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...

Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

U.S. equities finished higher during the third quarter, with 10 of 11 GICS sectors posting positive returns. Click here to ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...